Panel discussion on large molecule quantification by LC–MS

Michael completed postgraduate work at the University of Wales (Bangor, UK) and began work for the government in the UK, measuring the concentrations of pollutants in aquatic samples by gas and later liquid chromatography-mass spectrometry. He later joined the pharmaceutical industry with Sanofi (Guildford, UK), as a mass spectrometrist, doing bioanalytical and drug metabolism studies. Since then he has worked as a Principle Investigator and Head of Method Development at Covance (Alnwick, UK) and latterly for ARCINOVA as a method developer. The development of better insulin assays using hybrid MS approaches has been a major interest for about 10 years.

Kees Bronsema, Senior Scientist in Bioanalytical Method Development LC–MS/MS at PRA (Groningen, Netherlands), has nearly 20 years of experience in the field. Initially, the focus was on small molecule quantitation but following the trend towards biopharmaceuticals, he completed postgraduate work on absolute quantitation of proteins and peptides with LC–MS/MS at the University of Groningen (Groningen, Netherlands) in 2015. His current role is to develop analytical methods for proteins and peptides with LC–MS/MS, which include both endogenous biomarkers and biopharmaceuticals.

Cory is a Senior R&D Scientist in the Liquid Separations R&D group at MilliporeSigma, Bellefonte, PA. He completed his graduate studies at Youngstown State University in 2013, focusing on the analysis and characterization of oxidized proteins. Upon graduation, Cory joined MilliporeSigma in 2013, first joining the chemical standards R&D group, then transferring to the liquid separations R&D group. His current role at MilliporeSigma is to research, develop, and present on new particle technology for improved chromatographic separations of both small and large molecules as well as to develop new methodologies for characterizing biomacromolecules by several modes of chromatography.

*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

Dr Omnia Ismaiel is a Senior Research Scientist at Bioanalytical Labs, Pharmaceutical Product Development, USA. She is also an Associate Professor of Pharmaceutical Analytical Chemistry at Faculty of Pharmacy (Zagazig University, Egypt) and Affiliate Assistant Professor at School of Pharmacy (Virginia Commonwealth University, VA, USA). She was a Postdoctoral Fellow at Virginia Commonwealth University and a Postdoctoral Research Associate at University of Georgia, USA. She has been in the Bioanalysis field for more than 12 years. and has many years of teaching experience too. She is currently working on development and validation of Bioanalytical LC–MS methods for therapeutic peptides/proteins, glycan analysis and high-resolution MS.

Robert is a principal scientist at LGC where he leads of a group of scientists focused on providing a large molecule LC-MS bioanalytical service. He has expertise in the bioanalysis of small molecules, oligonucleotides, peptides and proteins utilizing LC-MS/MS and ligand binding assay technologies. He has developed a keen interest in the implementation of immunoaffinity, 2D-LC and HR-MS techniques for protein LC-MS quantification workflows.

Hongbin Yu is the Director of Bioanalytical Mass Spectrometry in the DMPK department at Boehringer Ingelheim Pharmaceuticals in Ridgefield (CT, USA). He obtained his Ph.D in organic chemistry from the University of Missouri-Columbia (MO, USA). He joined Boehringer Ingelheim in 2006 and has supported drug development for both small and large molecules. For small molecules, his responsibilities focused on biotransformation and bioanalysis utilizing LC–MS. For large molecules, his responsibilities included supervising immunoassay development/validation, critical reagent generation and pharmacokinetic analysis. He currently oversees regulated and non-regulated bioanalysis for small molecules by LC–MS and large molecules by hybrid LBA/LC–MS.